Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Oct 28, 2019 7:00 AM - Oct 30, 2019 12:30 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Session 7: Hot Topics

Session Chair(s)

Arthur A. Levin, PhD

Arthur A. Levin, PhD

Distinguished Scientist

Avidity Biosciences, United States

The hot topics session is designed to provide the attendees with a glimpse at future oligonucleotide therapeutics. This session is a chance to see how the field is developing and what kind of novel approaches or applications are being studied in academia and industry. With this early look at these approaches, it is hoped that the audience can envision the promise of new technologies and have a preview of the kind of challenges these technologies will face or pose to the current regulatory environment.


Robert  Ward


Robert Ward

Eloxx Pharmaceuticals, United States

Chairman and CEO

Jennifer  Panagoulias, RAC

Experience with FDA’s Complex Innovative Design (CID) Pilot

Jennifer Panagoulias, RAC

Consultant, United States

Regulatory Affairs and Compliance Consultant

Charles R Allerson, PhD

Charles R Allerson, PhD

DTx Pharma, Inc., United States

VP of Chemistry and Drug Development

Chantal  Ferguson

Potent siRNA Silencing in the Brain

Chantal Ferguson

University of Massachusetts Medical School, United States

MD/PhD Candidate

Daniele  Merico

Daniele Merico

Deep Genomics Inc., Canada

Director of Molecular Genetics

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.